SCHEMBL23744103

SCHEMBL23744103

COc1ccc2nc(N3C[C@@H](C)NC[C@@H]3C)cnc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 1/20 0.42
ALDH1A1 P00352 4/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
MAPT P10636 2/20 0.40
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PIM1 P11309 1/20 0.39
HCRTR1 O43613 5/20 0.38
HCRTR2 O43614 5/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
NQO2 P16083 1/20 0.38
KMT2A Q03164 1/20 0.38
HDAC1 Q13547 1/20 0.37
F2 P00734 1/20 0.36
GLA P06280 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23744102 0.83 MCHR1 (0.40) MCHR1NPC1RAB9APIM1HCRTR1
SCHEMBL30345489 0.83 MCHR1 (0.40) MCHR1NPC1RAB9APIM1HCRTR1
SCHEMBL13666118 0.81 HCAR2 (0.46) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL30345740 0.81 MCHR1 (0.42) MCHR1PIM1KDM4EHDAC1ROCK2
SCHEMBL23744803 0.81 MCHR1 (0.42) MCHR1PIM1KDM4EHDAC1ROCK2
SCHEMBL23744101 0.80 NPC1 (0.48) MCHR1ALDH1A1NPC1RAB9AMAPT
SCHEMBL30345769 0.80 NPC1 (0.48) MCHR1ALDH1A1NPC1RAB9AMAPT
SCHEMBL23744761 0.78 ALDH1A1 (0.48) MCHR1ALDH1A1NPC1RAB9AMAPT
SCHEMBL23744762 0.78 ALDH1A1 (0.48) MCHR1ALDH1A1NPC1RAB9AMAPT
SCHEMBL26090094 0.76 HCAR2 (0.50) ALDH1A1NPC1RAB9AMAPTPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 MCHR1 134/4885ALDH1A1 1378/4885NPC1 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.